Medical devices, healthcare technology and the business of care
510(k) clearance · K262807

VITEK 2 AST-Gram Negative Polymyxin B (<= 0.25 >=16µg/mL);VITEK 2 AST-Gram Negative Imipenem (<= 0.25 >=16µg/mL);VITEK 2 AST-Gram Negative Ceftazidime Avibactam (<= 0.125 >=16µg/mL)

BIOMERIEUX, Inc. · Decision date Nov 4, 2026

MEDTECHLEDGER EXPLANATIONK262807

What did the FDA decide?

The FDA recorded a substantially equivalent (SESE) decision on 11/04/2026 for K262807, a traditional 510(k) submitted by BIOMERIEUX, Inc. of Hazelwood, Missouri, and received 08/07/2026. The cleared device name covers three VITEK 2 AST-Gram Negative antimicrobial susceptibility test configurations: Polymyxin B (<= 0.25 – >=16 µg/mL), Imipenem (<= 0.25 – >=16 µg/mL) and Ceftazidime Avibactam (<= 0.125 – >=16 µg/mL). The regulation is 21 CFR 866.1645, product code LON, with subsequent codes LTT and LTW, in the Microbiology specialty and review panel. SESE denotes 510(k) clearance, not PMA approval.

The page lists the review as not conducted by a third party, not a combination product, and states a Predetermined Change Control Plan was authorized. The decision summary PDF is linked but its contents are not included here, so the analytical performance data supporting clearance, the claimed organism coverage and any labeling conditions remain unknown from this record. No clinical or comparative conclusions are drawn beyond the recorded decision.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Microbiology
Decision date
Nov 4, 2026
FDA decision documents: 510(k) Premarket Notification

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K262807
Regulatory pathway
510(k) premarket notification
Product code
LON
Decision code
SESE
Decision date
Nov 4, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: System, Test, Automated, Antimicrobial Susceptibility, Short Incubation.

Product code
LON
FDA device class
2

FDA decision timeline

  1. K262807 received

    Application receipt date recorded by FDA.

  2. K262807 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code LON

Product / regulatory recordCompanyPathwayDecision dateSource
VITEK PROK262683
bioMérieux, Inc.510(k) clearanceNov 3, 2026FDA
BIOMERIEUX, Inc.510(k) clearanceOct 1, 2026FDA
bioMérieux, Inc.510(k) clearanceSep 28, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

BIOMERIEUX, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Hazelwood, MO

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records